Brii Biosciences Ltd

Brii Biosciences Ltd maintains a strong liquidity position, with a current ratio of 60.73, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to CNY 606.84 million, which is a substantial portion of its total assets of CNY 2.36 billion. The price-to-book ratio of 0.41 suggests that the company is trading at a discount relative to its book value, which may reflect market skepticism about its current earnings potential. The company's profitability metrics are negative, with a return on equity (ROE) of -9.37% and a return on assets (ROA) of -9.43%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The net income of -CNY 222.62 million and operating income of -CNY 220.21 million further underscore the company's current financial challenges. Brii Biosciences Ltd's revenue is primarily concentrated in the domestic market, as disclosed in its business operations. The company's revenue for the latest period is CNY 18.61 million, which is relatively low compared to its total assets. This suggests that the company is in an early stage of development, with a focus on research and development rather than revenue generation. The company's growth trajectory is uncertain, with no immediate revenue growth expected in the current fiscal year. The operating cash flow of -CNY 338.81 million and free cash flow of -CNY 345.06 million indicate that the company is not generating positive cash flows from its operations. The capital expenditure of -CNY 126.73 million suggests that the company is investing in its operations, but the negative value indicates a reduction in capital spending. The risk assessment for Brii Biosciences Ltd indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is assessed as low. The company's debt-to-equity ratio of 0.0 suggests that it is not leveraging debt to finance its operations, which reduces financial risk. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's market price is CNY 1.34, and the market capitalization is CNY 967.16 million. Analyst estimates suggest a mean price target of CNY 2.00, with a median price target of CNY 2.00, indicating a potential upside for investors.